-
Beclin1, Ferroptosis, and Doxorubicin Liver Injury
2026-08-29
The reference study identifies Beclin1 as a driver of doxorubicin-associated liver injury through coordinated promotion of ferroptosis and excessive autophagy. Its findings position DHODH as a protective downstream target and show how biochemical, imaging, and protein-interaction assays can be combined to interpret hepatic oxidative damage.
-
MTT Assay Workflow for Cell Viability
2026-08-28
MTT converts cellular reducing activity into an accessible purple formazan signal, making it useful for proliferation, cytotoxicity, and treatment-response studies. This workflow shows how to apply MTT to radiation-triggered chemotherapy research while controlling for metabolic and optical confounders.
-
CD28–ARS2–PKM2 Flexibility in CD8+ T Cells
2026-08-27
A 2024 study identifies a CD28–ARS2 signaling axis that reshapes alternative splicing of PKM and promotes PKM2-dependent metabolic flexibility in activated CD8+ T cells. Its findings connect costimulatory signaling to glucose utilization, interferon-γ production, and antitumor immunity through a mechanism that is distinct from canonical CD28–PI3K signaling.
-
Morning Training Improves Endurance Adaptation in Mice
2026-08-27
Hesketh et al. show that endurance training during the early active phase produces larger performance gains than training during the late active phase, even when the early-phase group completes less absolute work. The findings identify exercise timing as an experimental variable that can influence training efficiency, muscle remodeling, and the interpretation of glycogen-related metabolic measurements.
-
Central Control of Opioid Mechanical Hypersensitivity
2026-08-26
The 2024 Neuron study by Yin et al. identifies a brain-to-spinal opioid circuit linking lateral parabrachial MOR neurons, hypothalamic dynorphin neurons, and spinal dorsal-horn KOR-GABA neurons to morphine-induced mechanical hypersensitivity and analgesic tolerance. Its findings distinguish mechanical opioid side effects from better-established thermal mechanisms and provide a circuit framework for targeted pain mechanism research.
-
Ellagic acid for CK2 Assay Workflows
2026-08-26
Ellagic acid provides a practical, ATP-competitive route to interrogate CK2 signaling in biochemical, cancer-cell, oxidative stress, and apoptosis assays. This workflow emphasizes solvent control, concentration design, orthogonal validation, and careful interpretation when extending CK2 studies into senescence research.
-
Mono-ADP-Ribosylation as a Degradation Signal
2026-08-25
A recent study shows that blocking ubiquitylation or proteasomal turnover can reveal otherwise transient endogenous ADP-ribosylation events. The work identifies DTX2 as an E3 ligase that promotes degradation of ADP-ribosylated PARP7, AHR, and related substrates during AHR activation, establishing mono-ADP-ribosylation as a regulated degradation mark.
-
Plantaricin A Sensitizes Gram-Negative Bacteria
2026-08-25
The reference study shows that engineered plantaricin A analogs can increase Gram-negative outer-membrane permeability and restore activity to hydrophobic antibiotics. Its lead analog, OP4, improved erythromycin activity, slowed resistance development in Escherichia coli, and showed efficacy in a mouse sepsis model, while also illustrating the safety and translational questions that remain.
-
Porcupine Inhibition in Severe Sclerosteosis
2026-08-24
A 2025 Bone Research study tested the PORCN inhibitor LGK974 as a pharmacological strategy for SOST-deficient sclerosteosis, targeting excessive Wnt/β-catenin activity rather than relying exclusively on high-risk surgery. The authors found reduced osteoblast activity and measurable decreases in trabecular and cortical bone phenotypes in Sost-deficient mice, while also identifying a sex-dependent difference in pathway biomarker response.
-
Chlorpromazine in Receptor and Nanoparticle Assays
2026-08-24
Build more interpretable dopamine receptor signaling and antiemetic assays with chlorpromazine hydrochloride, while using hepatic nanoparticle findings to improve cell-selection and uptake study design. This practical guide covers formulation, dose-response workflows, cross-domain limitations, and troubleshooting for reproducible chlorpromazine for research use.
-
DPPH Assay Workflow for Antioxidant Screening
2026-08-23
Turn the violet-to-yellow DPPH response into a practical ranking tool for purified compounds, natural extracts, and cultivation samples. This workflow combines plate-based radical scavenging measurements with orthogonal assays and LC-MS/MS to distinguish reproducible antioxidant hits from solvent, color, and matrix artifacts.
-
PS Nanoplastics, NMNAT3, and Placental Ferroptosis
2026-08-22
This study identifies an NMNAT3-dependent metabolic cascade linking gestational polystyrene nanoplastic exposure to placental mitochondrial dysfunction, ferritinophagy, ferroptosis, and fetal growth restriction. Its integrated metabolomics, cellular rescue, and nicotinamide-intervention strategy provides a mechanistic framework for studying nanoplastic-induced reproductive toxicity and potential metabolic countermeasures.
-
CCK-8 Signals for Osteoblast Translation
2026-08-22
Mechanistic osteoblast research requires more than a viability readout. This thought-leadership guide shows how Cell Counting Kit-8 (CCK-8) can strengthen experimental interpretation around the Prmt1–Ddx17–Sh2b1 axis while clarifying the assay’s translational opportunities and limitations.
-
Biotin Azide for Fzd5 Click-Labeling
2026-08-21
Biotin Azide converts terminal-alkyne biomolecules into affinity handles for streptavidin capture, detection, and interaction studies. This article adapts that chemistry to mechanistic assays inspired by cholesterol-sensitive Frizzled5 signaling while emphasizing controls, copper management, and workflow reproducibility.
-
BCA Quantification for BBB Translation
2026-08-20
A mechanistic and strategic guide to using bicinchoninic acid protein quantification to strengthen translational studies of α7nAChR-driven endothelial pyroptosis and HIV-1 gp120-associated blood–brain barrier injury.